GWM
ACAD icon

Geneos Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Geneos Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,425
Closed -$30.4K – 2460
2025
Q3 		$30.4K Buy
1,425
+756
+113% +$17.9K ﹤0.01% 1560
2025
Q2 		$14.4K Buy
669
+50
+8% +$929 ﹤0.01% 2171
2025
Q1 		$10.3K Buy
619
+284
+85% +$5.16K ﹤0.01% 2239
2024
Q4 		$6.15K Buy
335
+57
+21% +$920 ﹤0.01% 2254
2024
Q3 		$4.28K Buy
+278
New +$4.64K ﹤0.01% 2117
2022
Q3 		– Sell
-450
Closed -$6K – 1996
2022
Q2 		$6K Hold
450
– – ﹤0.01% 2111
2022
Q1 		$10K Hold
450
– – ﹤0.01% 2078
2021
Q4 		$10K Hold
450
– – ﹤0.01% 2161
2021
Q3 		$7K Hold
450
– – ﹤0.01% 2326
2021
Q2 		$10K Hold
450
– – ﹤0.01% 2186
2021
Q1 		$9K Hold
450
– – ﹤0.01% 2402
2020
Q4 		$11K Hold
450
– – ﹤0.01% 2166
2020
Q3 		$18K Hold
450
– – ﹤0.01% 1689
2020
Q2 		$21K Hold
450
– – ﹤0.01% 1587
2020
Q1 		$17K Hold
450
– – ﹤0.01% 1566
2019
Q4 		$19K Hold
450
– – ﹤0.01% 1701
2019
Q3 		$16K Sell
450
-417
-48% -$12.6K ﹤0.01% 1698
2019
Q2 		$23K Hold
867
– – ﹤0.01% 1557
2019
Q1 		$23K Hold
867
– – ﹤0.01% 1496
2018
Q4 		$13K Hold
867
– – ﹤0.01% 1680
2018
Q3 		$17K Sell
867
-2,300
-73% -$36.2K ﹤0.01% 1641
2018
Q2 		$48K Hold
3,167
– – ﹤0.01% 1062
2018
Q1 		$71K Buy
3,167
+3,017
+2,011% +$83.5K 0.01% 864
2017
Q4 		$4K Buy
+150
New +$4.8K ﹤0.01% 1853
2017
Q2 		– Sell
-63
Closed -$2K – 2066
2017
Q1 		$2K Hold
63
– – ﹤0.01% 1851
2016
Q4 		$1K Hold
63
– – ﹤0.01% 1917
2016
Q3 		$2K Buy
+63
New +$2.14K ﹤0.01% 1739
2016
Q2 		– Sell
-1,000
Closed -$28K – 1800
2016
Q1 		$28K Buy
+1,000
New +$21.8K ﹤0.01% 983

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geneos Wealth Management's ACAD Position: Q4 2025 in Review

Geneos Wealth Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 1,425 shares — an estimated $30.4K sold.

Geneos Wealth Management first reported a position in ACAD in Q1 2016 and held it in 28 quarters. The position peaked at $71K in Q1 2018. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Geneos Wealth Management reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 1,425 Acadia Pharmaceuticals shares in Q4 2025, an estimated $30.4K.
  • Geneos Wealth Management first reported a position in Acadia Pharmaceuticals in Q1 2016 and held it in 28 quarters.
  • Geneos Wealth Management's Acadia Pharmaceuticals position peaked at $71K in Q1 2018.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Geneos Wealth Management's 13F filing for Q4 2025, filed 28 Jan 2026.